Status:
COMPLETED
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Lead Sponsor:
Saegis Pharmaceuticals
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
Detailed Description
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The prim...
Eligibility Criteria
Inclusion
- 55 to 90 years of age
- Diagnosed with mild to moderate Alzheimer's disease
- Willing caregiver
- In general good health
Exclusion
- Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
- Prohibited Meds:
- Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00093951
Start Date
April 1 2004
End Date
September 1 2007
Last Update
December 11 2009
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85013
2
Dedicated Clinical Research
Sun City, Arizona, United States, 85351
3
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States, 85741
4
Clinical Trials Incorporated
Little Rock, Arkansas, United States, 72205